The blockade of this checkpoint has demonstrated potential therapeutic benefits, revealing a decrease in tumor growth and an increase in the efficacy of other immunotherapeutic strategies when the inhibitory effects of CD24 are neutralized (148). The gene discussed is CD24; the disease is neoplasm.